DATED 6 DECEMBER 2019 SUMMIT THERAPEUTICS PLC and MAKY ZANGANEH & ASSOCIATES, INC. CONSULTANT WARRANT AGREEMENTConsultant Warrant Agreement • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations
DATED 6 DECEMBER 2019 PLACING AGREEMENT RELATING TO A PLACING OF UP TO 9,221,400 ORDINARY SHARES AND 1,383,210 WARRANTS TO SUBSCRIBE FOR ORDINARY SHARES IN SUMMIT THERAPEUTICS PLCPlacing Agreement • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
DATE: 6 DECEMBER 2019 DEED OF TERMINATION OF A RELATIONSHIP AGREEMENT DATED 14 DECEMBER 2018 Between SUMMIT THERAPEUTICS PLC ROBERT W. DUGGAN and CAIRN FINANCIAL ADVISERS LLP CMS Cameron McKenna Nabarro Olswang LLP Cannon Place London EC4N 6AF T +44...Deed of Termination • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations • England
CONSULTING AGREEMENTConsulting Agreement • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations • California
This Consulting Agreement (the “Agreement”) dated December 6, 2019 is entered into by and between Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the “Company”), having a principal place of business at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, United Kingdom, and Maky Zanganeh & Associates, Inc., a California corporation (“Consultant”), having a business address at 2882 Sand Hill Rd., Suite 106, Menlo Park, California 94025, United States of America. The Company and Consultant are each a “Party” hereunder and collectively “the Parties.” The Agreement will be effective upon the date of Admission (as such term is defined in the Company’s circular to shareholders dated on or around the date of this Agreement in connection with a proposed equity investment in the Company by Robert Duggan) (the “Effective Date”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 6, 2019 by and among Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales, with its principal place of business at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, United Kingdom (the “Company”), and the investor named on Exhibit A hereto (the “Investor”).
